ClinicalTrials.gg
TerminatedNCT00150319Updated Sep 29, 2008

An Open-Label Study To Assess The Pharmacokinetics, Safety And Toleration Of Vfend®; Following Multiple Dosing With Vfend

A Phase 1/2 interventional study of Vfend®; I.V. in Kidney Failure, sponsored by Pfizer. Terminated at 6 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2008-09-29.

Sponsored by Pfizer · Phase 1/2 and Interventional

Why this study was terminated
See Detailed Description

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies in Renal Insufficiency by Pfizer — 2 open to participants now, 3 under way, none of them phase 3. Renal Insufficiency · Pfizer.

Enrollment
36th of 36
1 · median 30
Started
2005
with 2 others
Phase 1/2
Only one
of the 37
Registered
1st of 37
by date

Among the 37 studies in Renal Insufficiency by Pfizer, this one is the 36th largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2005, is the only one in phase 1/2, and was the 1st registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 37 studies in Renal Insufficiency by Pfizer are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Renal Insufficiency by Pfizer, or all of them as a file.
02

Study summary

This is a study to investigate the pharmacokinetics, safety and tolerability of intravenous voriconazole and SBECD in patients with moderate renal insufficiency

Read the detailed description

The study was put on hold after the first subject was enrolled and experienced a serious adverse event (SAE) of renal failure chronic after receiving his I.V. dose on Day 1. The study was taken off hold after the subject recovered and an independent consultant had deemed the SAE as not treatment related; however, the site was unwilling to enroll additional subjects. Another site, based in New Orleans, was damaged by hurricane Katrina and was unable to enroll any subjects. A decision was made by the sponsor to terminate the study on 11 Apr 2006 due to poor study enrollment. There were no safety or efficacy concerns regarding the study in the decision to terminate the trial.

03

Conditions studied

  • Kidney Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with moderate renal insufficiency

Exclusion criteria

Exclusion Criteria:

  • Active infection
05

Study design

Phase
Phase 1 / Phase 2
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Ability to tolerate up to seven days of intravenous voriconazole without worsening of pre-existing renal insufficiency

07

Study locations

6 sites
  • Pfizer Investigational Site
    New Orleans, Louisiana 70118, United States
  • Pfizer Investigational Site
    New Orleans, Louisiana 70119, United States
  • Pfizer Investigational Site
    Minneapolis, Minnesota 55404, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37920, United States
  • Pfizer Investigational Site
    Austin, Texas 78727, United States
  • Pfizer Investigational Site
    Austin, Texas 78758, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Oct 2005 and a completion of Oct 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2005
First posted
Sep 8, 2005
Start
Jun 2005
Primary completionActual
Oct 2005
CompletionActual
Oct 2005
Last update
Sep 29, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00150319
Lead sponsor
Pfizer
First posted
Sep 8, 2005
Start date
Jun 2005
Primary completion
Oct 2005
Completion
Oct 2005
Last update
Sep 29, 2008

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Voriconazole

Start the discussion